News Releases
Nov 13, 2023
ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update Read more
Nov 1, 2023
ALX Oncology Announces November Investor Conference Participation Read more
Oct 10, 2023
ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares Read more
Oct 5, 2023
ALX Oncology Announces Pricing of Public Offering Read more
Oct 4, 2023
ALX Oncology Announces Proposed Public Offering Read more
Oct 3, 2023
ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer Read more
Oct 2, 2023
ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer Read more
Sep 6, 2023
ALX Oncology Realigns Executive Leadership Team Read more
Aug 31, 2023
ALX Oncology Announces September Investor Conference Participation Read more
Aug 10, 2023
ALX Oncology Reports Second Quarter 2023 Financial Results and Provides Clinical Program Update Read more